PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV
Authors:
- Jing-Yi YangJYJing-Yi Yang
- Hui-Min YanHYHui-Min Yan
- 7 April 2011
- journal article
- Published by Elsevier in Virologica Sinica
- Vol. 26 (2) , 81-94
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- An Adjuvant for the Induction of Potent, Protective Humoral Responses to an H5N1 Influenza Virus Vaccine with Antigen-Sparing Effect in MiceJournal of Virology, 2010
- A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemicVaccine, 2009
- Effects of Different Immunization Protocols and Adjuvant on Antibody Responses to Inactivated SARS-CoV VaccineViral Immunology, 2008
- Quantitative temporal‐spatial distribution of severe acute respiratory syndrome‐associated coronavirus (SARS‐CoV) in post‐mortem tissuesJournal of Medical Virology, 2007
- A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in miceInternational Immunology, 2004
- Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal ImmunizationJournal of Virology, 2002
- INTERACTION OF ANTIGENS AND ANTIBODIES AT MUCOSAL SURFACESAnnual Review of Microbiology, 1997
- When Two Strands Are Better Than One: The Mediators and Modulators of the Cellular Responses to Double-Stranded RNAVirology, 1996
- A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effectsArchives of Virology, 1993
- Immunologic‐mediated Protection of Trypanosoma congolense‐Infected Mice by PolyribonucleotidesThe Journal of Protozoology, 1971